- Conditions
- Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Leiomyosarcoma, Adult Malignant Fibrous Histiocytoma, Adult Neurofibrosarcoma, Adult Synovial Sarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma
- Interventions
- sorafenib tosylate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 248
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neuroma
- Interventions
- Regenerative Peripheral Nerve Interface (RPNI) surgery, Traction Neurectomy
- Procedure
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Ann Arbor, Michigan
- Conditions
- Neoplasms, Adenomatous Polyposis Coli, Neurofibroma, Plexiform, Myelodysplastic Syndromes
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neurofibromatosis 1
- Interventions
- Abemaciclib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Endometrial Cancer, Ovarian Cancer, Sarcoma
- Interventions
- temozolomide
- Drug
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Acute Lymphoblastic Leukemia, Neurofibromatosis Type 1
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 35 Years
- Enrollment
- 1,720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neurofibromatosis 1 (NF1), Neurofibromatosis Type I
- Interventions
- GentleMax Pro (with skin cooling), GentleMax Pro (without skin cooling)
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Neurofibromatosis Type 1, Neurofibromatosis 1, Neurofibromatosis (Nonmalignant), Cutaneous Neurofibroma
- Interventions
- Evaluation of the natural history of cutaneous neurofibromas
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 1 Year to 100 Years
- Enrollment
- 500 participants
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Neurofibromatosis Type 1, Plexiform Neurofibroma
- Interventions
- Binimetinib
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more
- Conditions
- Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1)
- Interventions
- Mirdametinib (PD-0325901) oral capsule or dispersible tablet
- Drug
- Lead sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 37 more
- Conditions
- Post-Mastectomy Chronic Pain Syndrome
- Interventions
- Regenerative Peripheral Nerve Interface
- Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Spinal Metastases, Vertebral Metastases, Benign Spinal Tumors, Chordoma, Meningioma, Schwannoma, Neurofibroma, Paragangliomas, Arteriovenous Malformations
- Interventions
- SBRT for Benign Extradural Spine Tumors, SBRT for Vertebral/Paraspinal Metastases
- Radiation
- Lead sponsor
- Mercy Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Neurofibromatosis Type 1
- Interventions
- Lovastatin ™, placebo
- Drug · Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 8 Years to 15 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Neurofibromatosis Type 1, Plexiform Neurofibroma, Spinal Cord Neurofibroma
- Interventions
- Cediranib Maleate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
- Conditions
- Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
- Interventions
- MRTX1719
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Lone Tree, Colorado • Jacksonville, Florida + 20 more
- Conditions
- Acoustic Neuroma, Labyrinthitis Ossificans, Profound Hearing Impairment
- Interventions
- MedEl Test Electrode Placer
- Device
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Farmington Hills, Michigan
- Conditions
- Neurofibromatosis Type 1
- Interventions
- Magnetic resonance imaging, Gadolinium contrast
- Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 1 Year to 7 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Neurofibromatosis 1, Neurofibroma, Atypical Neurofibroma, Atypical Neurofibromatosis, Plexiform Neurofibroma, Von Recklinghausen Disease
- Interventions
- Whole Body MRI
- Diagnostic Test
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 8 Years to 30 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
- Interventions
- Panitumumab-IRDye800
- Drug
- Lead sponsor
- Eben Rosenthal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Vestibular Schwannoma
- Interventions
- Microsurgical resection of VS, Stereotactic radiosurgery, PREHAB
- Procedure · Radiation · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Neurofibromatosis 1, Plexiform Neurofibroma
- Interventions
- Cabozantinib Oral Tablet, Selumetinib Oral Capsule
- Drug
- Lead sponsor
- Girish Dhall, MD
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Neuroma, Acoustic
- Interventions
- Microsurgery, Stereotactic radiation therapy
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2022
- U.S. locations
- 9
- States / cities
- Stanford, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more
- Conditions
- Neurofibromatosis Type 1
- Interventions
- Not listed
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 6 Years to 9 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneuronal Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
- Interventions
- dabrafenib, trametinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 99 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Miami, Florida + 8 more